Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Elevance Health (ELV) Stock Stays Undervalued Despite Its 37% Run - simplywall.st

AI-generated analysis

πŸ“‰ Elevance Health (ELV) has returned 37.5% over the last 12 months, raising questions about whether recent gains have fully priced in its fundamentals.

πŸ“Š The stock trades at a P/E ratio of 18.1x, which is materially lower than the healthcare industry average of 25.3x and peer group average of 27.8x.

🎯 Analysts estimate a fair P/E multiple for Elevance Health of 34.8x, suggesting the current market price implies a significant undervaluation gap.

πŸ‘€ Dr. Patrick Fox has been appointed to lead Carelon Behavioral Services to support expectations for profitable growth in that segment.

πŸ€– The company is expanding its use of AI and technology investments to boost efficiency and reduce operational costs.

⚠️ Elevated costs associated with government-backed plans pose a risk of compressing margins despite ongoing operational improvements.

πŸ₯ Greater reliance on value-based care models could further impact profitability if execution challenges arise during scaling efforts.

Bullish Signals
  • Elevance Health trades at a P/E ratio of 18.1x, which is substantially below the healthcare industry average of 25.3x and peer group average of 27.8x.
  • Analysts estimate a fair P/E multiple of 34.8x for Elevance Health, indicating the current market price may be significantly undervalued relative to fundamentals.
  • The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services is expected to support profitable growth in that specific business segment.
Risk Factors
  • Elevated costs in government-backed plans could compress margins despite the company's operational improvements and diversification strategies.
  • Greater reliance on value-based care models presents a risk of margin pressure if execution challenges arise during scaling efforts.
Full Analysis
Elevance Health (ELV) has gained 37.5% over the past 12 months, yet analysts at Simply Wall St argue the stock remains undervalued based on fundamental metrics. The company currently trades at a Price-to-Earnings ratio of 18.1x, which is significantly lower than the wider healthcare industry average of 25.3x and its peer group average of 27.8x. Despite recent share price strength, valuation models suggest a fair P/E multiple closer to 34.8x, implying a substantial gap between current market pricing and estimated intrinsic value. The article highlights that while the stock has rallied, it still screens as inexpensive relative to both historical benchmarks and comparable healthcare peers. Key drivers for future performance include the appointment of Dr. Patrick Fox to lead Carelon Behavioral Services and increased adoption of AI technologies aimed at boosting operational efficiency. However, risks remain regarding elevated costs in government-backed plans and the potential margin compression from a greater reliance on value-based care models.